[ CAS No. 19064-18-7 ] {[proInfo.proName]}

Name: 19064-18-7|(2,6-Difluorophenyl)methanol|98%
Brand: Ambeed
SKU: A129435
Price: 6.0 USD
Availability: InStock
Rating: 98 (28 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 19064-18-7

Structure of 19064-18-7 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 19064-18-7 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 19064-18-7 ]

SDS Specification

Alternatived Products of [ 19064-18-7 ]

Product Details of [ 19064-18-7 ]

CAS No. :	19064-18-7	MDL No. :	MFCD00004603
Formula :	C₇H₆F₂O	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	LVICICZQETYOGS-UHFFFAOYSA-N
M.W :	144.12	Pubchem ID :	87921
Synonyms :

Calculated chemistry of [ 19064-18-7 ]

Physicochemical Properties

Num. heavy atoms :	10
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.14
Num. rotatable bonds :	1
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	32.49
TPSA :	20.23 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.38 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.79
Log Po/w (XLOGP3) :	1.12
Log Po/w (WLOGP) :	2.15
Log Po/w (MLOGP) :	2.41
Log Po/w (SILICOS-IT) :	2.52
Consensus Log Po/w :	1.99

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	2.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.82
Solubility :	2.2 mg/ml ; 0.0152 mol/l
Class :	Very soluble
Log S (Ali) :	-1.14
Solubility :	10.5 mg/ml ; 0.0727 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-2.76
Solubility :	0.249 mg/ml ; 0.00173 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.0

Safety of [ 19064-18-7 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P305+P351+P338	UN#:	N/A
Hazard Statements:	H227-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 19064-18-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 19064-18-7 ]
Downstream synthetic route of [ 19064-18-7 ]

[ 19064-18-7 ] Synthesis Path-Upstream 1~8

1
[ 19064-18-7 ]
[ 437-81-0 ]

Reference： [1] RSC Advances, 2014, vol. 4, # 90, p. 48777 - 48782
[2] Chinese Journal of Chemistry, 2014, vol. 32, # 2, p. 117 - 122

2
[ 19064-18-7 ]
[ 105-56-6 ]
[ 437-81-0 ]
[ 790227-40-6 ]

Reference： [1] ChemCatChem, 2016, vol. 8, # 5, p. 929 - 937

3
[ 19064-18-7 ]
[ 697-73-4 ]

Reference： [1] Green Chemistry, 2016, vol. 18, # 18, p. 4947 - 4953
[2] Organic Process Research and Development, 2016, vol. 20, # 2, p. 568 - 573

4
[ 437-81-0 ]
[ 19064-18-7 ]

Reference： [1] Journal of Medicinal Chemistry, 1968, vol. 11, # 4, p. 814 - 819
[2] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 4, p. 1110 - 1113

5
[ 372-18-9 ]
[ 19064-18-7 ]

Reference： [1] Journal of Medicinal Chemistry, 1968, vol. 11, # 4, p. 814 - 819

6
[ 66464-26-4 ]
[ 19064-18-7 ]

Reference： [1] Tetrahedron Letters, 1993, vol. 34, # 31, p. 4893 - 4896

7
[ 19064-18-7 ]
[ 654-01-3 ]

Reference： [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 4, p. 1110 - 1113

8
[ 19064-18-7 ]
[ 217448-86-7 ]

Reference： [1] Green Chemistry, 2016, vol. 18, # 18, p. 4947 - 4953

[ 19064-18-7 ] Synthesis Path-Downstream 1~88

1
[ 437-81-0 ]
[ 19064-18-7 ]

Reference： [1]Journal of Medicinal Chemistry,1968,vol. 11,p. 814 - 819
[2]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 1110 - 1113

2
[ 66464-26-4 ]
[ 19064-18-7 ]

Reference： [1]Tetrahedron Letters,1993,vol. 34,p. 4893 - 4896

3
[ 19064-18-7 ]
[ 85118-00-9 ]

Reference： [1]Australian Journal of Chemistry,1984,vol. 37,p. 1437 - 1446
[2]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 1110 - 1113

4
[ 19064-18-7 ]
[ 5538-51-2 ]
2-(2,6-Difluoro-benzyloxy)-2-methyl-benzo[1,3]dioxin-4-one [ No CAS ]
2-Acetoxy-benzoic acid 2,6-difluoro-benzyl ester [ No CAS ]

Reference： [1]Acta Chemica Scandinavica,1989,vol. 43,p. 793 - 798
[2]Acta Chemica Scandinavica,1989,vol. 43,p. 793 - 798

5
[ 19064-18-7 ]
(1R,2R,3R,5R,6R)-2-Amino-3-(2,6-difluoro-benzyloxy)-6-fluoro-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 4570 - 4587

6
[ 19064-18-7 ]
(1R,2R,3R,5R,6R)-2-Amino-3-(2,6-difluoro-benzyloxy)-6-fluoro-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 4570 - 4587

7
[ 19064-18-7 ]
(1R,2R,3R,5R,6R)-2-Azido-3-(2,6-difluoro-benzyloxy)-6-fluoro-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid diethyl ester [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2004,vol. 47,p. 4570 - 4587

8
[ 19064-18-7 ]
[ 367488-53-7 ]

Reference： [1]Journal of Medicinal Chemistry,2001,vol. 44,p. 3083 - 3091

9
[ 19064-18-7 ]
(2R,3R,4R,5R)-2,5-Bis-(2,6-difluoro-benzyloxy)-3,4-dihydroxy-hexanedioic acid bis-[((S)-2-methyl-1-methylcarbamoyl-propyl)-amide] [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2001,vol. 44,p. 3083 - 3091

10
[ 19064-18-7 ]
(2R,3R,4R,5R)-2,5-Bis-(2,6-difluoro-benzyloxy)-3,4-dihydroxy-hexanedioic acid bis-[((1S,2R)-2-hydroxy-indan-1-yl)-amide] [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2001,vol. 44,p. 3083 - 3091

11
[ 19064-18-7 ]
[ 229346-88-7 ]

Reference： [1]Chemical and Pharmaceutical Bulletin,1999,vol. 47,p. 574 - 575

12
[ 19064-18-7 ]
[ 62037-91-6 ]

Reference： [1]Australian Journal of Chemistry,1984,vol. 37,p. 1437 - 1446

13
[ 372-18-9 ]
[ 19064-18-7 ]

Reference： [1]Journal of Medicinal Chemistry,1968,vol. 11,p. 814 - 819

14
[ 438050-09-0 ]
[ 19064-18-7 ]
(R)-2-ethyl-piperazine-1-carboxylic acid 2,6-difluoro-benzyl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Example 178 (R)-2-Ethyl-piperazine-1-carboxylic acid 2,6-difluoro-benzyl ester This compound was prepared from (R)-4-chlorocarbonyl-3-ethyl-piperazine-1-carboxylic acid tert-butyl ester and 2,6-difluorobenzylalcohol via (R)-2-ethyl-piperazine-1,4-dicarboxylic acid 4-tert-butyl ester 1-(2,6-difluoro-benzyl)ester according to the procedures described in Example 177 to give the product as a yellowish oil (69 mg); MS (ISP): 285.2 (M+H)+.

Reference： [1]Patent: US2002/143020,2002,A1

15
[ 438050-54-5 ]
[ 19064-18-7 ]
(R)-2,6-Difluorobenzyl 2-methylpiperazine-1-carboxylate hydrochloride [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
70%		Example 124 (R)-2,6-Difluorobenzyl 2-methylpiperazine-1-carboxylate hydrochloride was prepared from <strong>[19064-18-7]2,6-difluorobenzyl alcohol</strong> and (R)1-chlorocarbonyl-2-methyl-4-tert-butoxycarbonylpiperazine according to the methods described for Examples 52 and 54 to give the product as a white solid (0.217 g, 70% overall); (Found: C, 50.7; H, 5.65; N, 9.0. C13H16F2N2O2.HCl requires C, 50.9; H, 5.6; N, 9.1%); deltaH (400 MHz, DMSO-d6) 9.39 (2H, br), 7.50 (1H, m), 7.18-7.12 (2H, m), 5.17 (2H, m, J 12.4 Hz), 4.29 (2H, m), 3.88 (1H, d, J 13 Hz), 3.24-3.03 (4H, m, J 13 Hz), 2.86 (1H, m, J 12.4 Hz), and 1.24 (3H, d, J 7.2 Hz).

Reference： [1]Patent: US2002/143020,2002,A1

16
[ 170923-67-8 ]
[ 19064-18-7 ]
1-(2-Butenyl)-7-(2,6-difluorobenzyloxy)-2,3-dimethylpyrrolo[2,3-d]pyridazine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
58.3%		EXAMPLE 38 1-(2-Butenyl)-7-(2,6-difluorobenzyloxy)-2,3-dimethylpyrrolo[2,3-d]pyridazine The title compound (cis/trans=22/78) was prepared as a white powder in 58.3% yield in a similar procedure to that described in Example 1 by using 1-(2-butenyl)-7-chloro-2,3-dimethylpyrrolo[2,3-d]pyridazine (cis/trans=24/76) and <strong>[19064-18-7]2,6-difluorobenzyl alcohol</strong>. m.p.: 85-94 C. Mass spectrum (CI, m/z): 344 (M+ +1). NMR spectrum (CDCl3, deltappm): 1.46-1.60 (m, 3H), 2.26 (s, 3H), 2.31 (s, 3H), 4.65-4.79 (m, 1.56H), 4.86-4.94 (m, 0.44H), 5.09-5.51 (m, 2H), 5.78 (s, 2H), 6.87-7.02 (m, 2H), 7.27-7.42 (m, 1H), 8.98 (s, H). Elementary analysis. (%): Calc'd for C19 H19 F2 N3 O: C, 66.46; H, 5.58; N, 12.24, Found: C, 66.13; H, 5.45; N, 12.25.

Reference： [1]Patent: US6063782,2000,A

17
monosodium salt of imidazole-4,5-dicarboxylic acid diethyl ester [ No CAS ]
[ 1080-79-1 ]
[ 19064-18-7 ]
[ 124-63-0 ]
1-(2,6-difluorobenzyl)-imidazole-4,5-dicarboxylic acid diethyl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium; triethylamine; In ice-water; ethanol; dichloromethane; ethyl acetate; toluene;	(b) 13.0 g of 2,6-difluorobenzyl alcohol and 8.4 g of methanesulphonyl chloride are dissolved in 90 ml of methylene chloride, and 17.6 ml of triethylamine in 18 ml of methylene chloride are added dropwise while stirring in an ice bath. The rate at which the triethylamine is added is so regulated that the internal temperature does not exceed 10. The whole is stirred for a further 40 minutes in the ice bath and then 90 ml of ice-water are added and the whole is stirred for a further 60 minutes. The organic phase is separated off and dried over magnesium sulphate, and 21 g of the monosodium salt of <strong>[1080-79-1]imidazole-4,5-dicarboxylic acid diethyl ester</strong> (obtainable, for example, by reacting <strong>[1080-79-1]imidazole-4,5-dicarboxylic acid diethyl ester</strong> with 2.53 g of sodium dissolved in 60 ml of ethanol) are added. The whole is stirred for 3 hours at room temperature, washed three times with water, dried over magnesium sulphate, concentrated to dryness by evaporation, dissolved in toluene/ethyl acetate (1:1), filtered over silica gel, again concentrated to dryness by evaporation and recrystallized from ether/petroleum ether. 1-(2,6-difluorobenzyl)-<strong>[1080-79-1]imidazole-4,5-dicarboxylic acid diethyl ester</strong> having a melting point of 68-70 is obtained.

Reference： [1]Patent: US4851424,1989,A

18
[ 1897-52-5 ]
[ 19064-18-7 ]
[ 872181-36-7 ]

Reference： [1]Journal of Medicinal Chemistry,2008,vol. 51,p. 449 - 469

19
[ 326829-06-5 ]
[ 19064-18-7 ]
[ 326829-04-3 ]

Yield	Reaction Conditions	Operation in experiment
26%		2,6-Difluorobenzyl alcohol (0.2 ml, 1.8 mmol), thiourea (165 mg, 2.2 mmol),aqueous hydrochloric acid (2M) (2.7 ml) and 1,4-dioxane (3 ml) were mixed and themixture heated in a sealed vessel in the microwave at 140C for 10 minutes. Potassiumcarbonate (1.1 g, 8 mmol) and 3-methanesulfonyl-5,5-dimethyl-4,5-dihydroisoxazole(380 mg, 2.1 mmol) were added and the mixture was stirred in an open vessel for 10minutes. The mixture was heated in a sealed vessel in the microwave at 150C for 10minutes. The mixture was diluted with water and extracted with ethyl acetate. Theorganic extract was washed with water, dried over magnesium sulfate and concentrated.The crude material was purified by chromatography on silica gel (eluent: ethyl acetate /hexane) to give the product as a white solid (120 mg, 26% yield). M.p. 85-87C. ]H-NMR (400 MHz, CDC13): 1.43 (6H, s, Me), 2.82 (2H, s, CH2), 4.36 (2H, s, CH2), 6.90(2H, d, CH), 7.26 (1H, t, CH).

Reference： [1]Patent: WO2006/24820,2006,A1 .Location in patent: Page/Page column 137-138

20
[ 19064-18-7 ]
[ 140-29-4 ]
C₁₅H₉F₂N [ No CAS ]
[ 1309045-35-9 ]

Yield	Reaction Conditions	Operation in experiment
12%Chromat.; 54%Chromat.	In trifluorotoluene; at 180℃; for 32h;Inert atmosphere; Autoclave;	A mixture of benzyl alcohol (1 mmol), phenylacetonitrile (3 mmol), 0.0998 g of metal-MgO (Pd: 0.0075 mmol; Au: 0.0075 mmol; Pt: 0.0075 mmol), trifluorotoluene (1 ml) and n-dodecane (20 mul) as internal standard were placed into an autoclave. The resulting mixtures were vigorously stirred at 180 C under nitrogen, being monitored by GC.

Reference： [1]Journal of Catalysis,2011,vol. 279,p. 319 - 327

21
[ 75-44-5 ]
[ 19064-18-7 ]
[ 1427166-96-8 ]

Reference： [1]ACS Medicinal Chemistry Letters,2012,vol. 3,p. 1024 - 1028

22
[ 19064-18-7 ]
[ 1400654-66-1 ]

Reference： [1]ACS Medicinal Chemistry Letters,2012,vol. 3,p. 1024 - 1028

23
[ 19064-18-7 ]
C₁₈H₂₂F₂N₂O₅ [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2012,vol. 3,p. 1024 - 1028

24
[ 19064-18-7 ]
[ 32779-37-6 ]
[ 1415640-19-5 ]

Yield	Reaction Conditions	Operation in experiment
48%		Example 33 Preparation of 5-(2,2-difluoro-6-methylbenzo[d]1,3-dioxolen-5-yl)-2-[2,6-difluorophenyl)methoxy]pyrimidine (62) To a solution of 2,6-difluorobenzyl alcohol (288 mg, 2 mmol) in 10 ml dry THF was added sodium hydride (80 mg, 60% mineral oil dispersion, 2 mmol). The resulting suspension was stirred at r.t. for 30 min before addition of <strong>[32779-37-6]2,5-dibromopyrimidine</strong> (476 mg, 2 mmol). After stirred for 1 h at r.t. the reaction mixture was diluted with EA, worked up with aqueous sodium bicarbonate/brine. The organic phase was dried over sodium sulfate, concentrated, subjected to silica gel flash column using hexane and EA as eluents to give 290 mg 60 as white solid (yield: 48%).

Reference： [1]Patent: US2012/316182,2012,A1 .Location in patent: Page/Page column 95

25
[ 624-28-2 ]
[ 19064-18-7 ]
[ 1415640-22-0 ]

Yield	Reaction Conditions	Operation in experiment
41%		Example 35 Preparation of 5-(2,2-difluoro-6-methylbenzo[d]1,3-dioxolen-5-yl)-2-[2,6-difluorophenyl)methoxy]pyridine (66) To a solution of <strong>[19064-18-7]2,6-difluorobenzyl alcohol</strong> (288 mg, 2 mmol) in 10 ml dry THF was added sodium hydride (80 mg, 60% mineral oil dispersion, 2 mmol). The resulting suspension was stirred at r.t. for 30 min before addition of 2,5-dibromopyridine (474 mg, 2 mmol). After stirred overnight at 60 C. the reaction mixture was cooled down to r.t. and diluted with EA, worked up with aqueous sodium bicarbonate/brine. The organic phase was dried over sodium sulfate, concentrated, subjected to silica gel flash column using hexane and EA as eluents to give 246 mg of 65 as a colorless oil (yield: 41%).

Reference： [1]Patent: US2012/316182,2012,A1 .Location in patent: Page/Page column 96

26
[ 19064-18-7 ]
[ 1415640-20-8 ]

Reference： [1]Patent: US2012/316182,2012,A1

27
[ 19064-18-7 ]
[ 1415640-21-9 ]

Reference： [1]Patent: US2012/316182,2012,A1

28
[ 19064-18-7 ]
[ 1415640-23-1 ]

Reference： [1]Patent: US2012/316182,2012,A1

29
[ 19064-18-7 ]
[ 1415640-24-2 ]

Reference： [1]Patent: US2012/316182,2012,A1

30
[ 19064-18-7 ]
[ 654-01-3 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 1110 - 1113

31
[ 19064-18-7 ]
[ 108-98-5 ]
[ 882-33-7 ]

Reference： [1]Chemistry - A European Journal,2013,vol. 19,p. 17464 - 17471

32
[ 19064-18-7 ]
[ 437-81-0 ]

Reference： [1]RSC Advances,2014,vol. 4,p. 48777 - 48782
[2]Chinese Journal of Chemistry,2014,vol. 32,p. 117 - 122

33
[ 19064-18-7 ]
[ 95-55-6 ]
[ 152993-82-3 ]

Reference： [1]ACS Catalysis,2014,vol. 4,p. 1686 - 1692

34
[ 19064-18-7 ]
1-[4-[[6-[(2,6-difluorophenyl)methoxy]-3-pyridazinyl]oxy]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone [ No CAS ]

Reference： [1]Patent: WO2014/179144,2014,A1

35
[ 19064-18-7 ]
1,1-dimethylethyl 4-[6-[(2,6-diflurophenyl)methoxy]-3-pyridazinyl]oxy-1-piperidinecarboxylate [ No CAS ]

Reference： [1]Patent: WO2014/179144,2014,A1

36
[ 141-30-0 ]
[ 19064-18-7 ]
3-chloro-6-[(2,6-difluorophenyl)methoxy]pyridazine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
1.69 g		Step C: Preparation of 3-chloro-6-[(2,6-difluorophenyl)methoxypyridazine To a mixture of sodium hydride (60% dispersion in mineral oil, 960 mg, 24 mmol) in tetrahydrofuran (20 mL) was added dropwise <strong>[19064-18-7]2,6-difluorobenzenemethanol</strong> (1.15 g, 8 mmol) in tetrahydrofuran (4 mL). The reaction mixture was heat at 60 C and stirred for 1 h, and then 3,6-dichloropyridazine (3.58 g, 24 mmol) in tetrahydrofuran (10 mL) was added dropwise. The reaction mixture was stirred for 4 h at 55 C, cooled, and saturated aqueous sodium bicarbonate (10 mL) was added. The tetrahydrofuran was removed under reduced pressure and the resulting mixture was extracted with ethyl acetate. The combined organic extracts were dried over magnesium sulfate, filtered concentrated under reduced pressure. Water was added to the resulting material and the solid precipitate was collected by filtration, washed with water and dried to give the title compound (1.69 g). H NMR (CDCI3): delta 7.32-7.41 (m, 2H), 6.92-7.02 (m, 3H), 5.62 (s, 2H).

Reference： [1]Patent: WO2014/179144,2014,A1 .Location in patent: Page/Page column 62

37
[ 108-30-5 ]
[ 19064-18-7 ]
C₁₁H₁₀F₂O₄ [ No CAS ]

Reference： [1]Asian Journal of Chemistry,2014,vol. 26,p. 8025 - 8028

38
[ 19064-18-7 ]
3-(4-chloropyridin-2-yl)quinazoline-2,4(1H,3H)-dione [ No CAS ]
3-(4-((2,6-difluorobenzyl)oxy)pyridin-2-yl)quinazoline-2,4(1H,3H)-dione [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
31 mg		A mixture of <strong>[19064-18-7](2,6-difluorophenyl)methanol</strong> (1 mL) and sodium hydride (60%, oil) (34 mg) was stirred at room temperature for 30 min. 3-(4-Chloropyridin-2-yl)quinazoline-2,4(1H,3H)-dione (115 mg) was added, and the obtained mixture was stirred at 150C for 4 hr. The reaction mixture was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (31 mg). 1H NMR (300 MHz, DMSO-d6) delta 5.24 (2H, s), 7.14-7.31 (6H, m), 7.51-7.65 (1H, m),7.66-7.79 (1H, m), 7.87-8.06 (1H, m), 8.45 (1H, d, J = 5.7 Hz), 11.65 (1H, s).

Reference： [1]Patent: EP2889291,2015,A1 .Location in patent: Paragraph 0842

39
[ 106-42-3 ]
[ 19064-18-7 ]
2-(2,5-dimethylbenzyl)-1,3-difluorobenzene [ No CAS ]

Reference： [1]Organic and Biomolecular Chemistry,2019,vol. 17,p. 6007 - 6014
[2]Journal of the American Chemical Society,2015,vol. 137,p. 9694 - 9703

40
[ 19064-18-7 ]
[ 105-56-6 ]
[ 437-81-0 ]
[ 790227-40-6 ]

Reference： [1]ChemCatChem,2016,vol. 8,p. 929 - 937

41
[ 19064-18-7 ]
[ 697-73-4 ]

Reference： [1]Green Chemistry,2016,vol. 18,p. 4947 - 4953
[2]Organic Process Research and Development,2016,vol. 20,p. 568 - 573

42
[ 19064-18-7 ]
8-[(2,6-difluorobenzyl)oxy]-N-[(2S)-hexan-2-yl]-2,6-dimethylimidazo[1,2-a]pyrazine-3-carboxamide [ No CAS ]

Reference： [1]Patent: US2016/176880,2016,A1

43
[ 19064-18-7 ]
8-[(2,6-difluorobenzyl)oxy]-N-[(2R)-1-hydroxyhexan-2-yl]-2,6-dimethylimidazo[1,2-a]pyrazine-3-carboxamide [ No CAS ]

Reference： [1]Patent: US2016/176880,2016,A1

44
[ 19064-18-7 ]
8-[(2,6-difluorobenzyl)oxy]-N-[1-(3,4-difluorophenyl)cyclopropyl]-2,6-dimethylimidazo[1,2-a]pyrazine-3-carboxamide [ No CAS ]

Reference： [1]Patent: US2016/176880,2016,A1

45
[ 19064-18-7 ]
rac-N-(2-amino-2,4-dimethylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyrazine-3-carboxamide [ No CAS ]

Reference： [1]Patent: US2016/176880,2016,A1

46
[ 19064-18-7 ]
8-[(2,6-difluorobenzyl)oxy]-2,6-dimethyl-N-[(3S)-2-oxopyrrolidin-3-yl]imidazo[1,2-a]pyrazine-3-carboxamide [ No CAS ]

Reference： [1]Patent: US2016/176880,2016,A1

47
[ 19064-18-7 ]
8-[(2,6-difluorobenzyl)oxy]-N-(6-fluoroquinolin-4-yl)-2,6-dimethylimidazo[1,2-a]pyrazine-3-carboxamide [ No CAS ]

Reference： [1]Patent: US2016/176880,2016,A1

48
[ 19064-18-7 ]
8-[(2,6-difluorobenzyl)oxy]-N-[2-(1-hydroxycyclopentyl)ethyl]-2,6-dimethylimidazo[1,2-a]pyrazine-3-carboxamide [ No CAS ]

Reference： [1]Patent: US2016/176880,2016,A1

49
[ 19064-18-7 ]
8-[(2,6-difluorobenzyl)oxy]-N-(2-hydroxyethoxy)-2,6-dimethylimidazo[1,2-a]pyrazine-3-carboxamide [ No CAS ]

Reference： [1]Patent: US2016/176880,2016,A1

50
[ 19064-18-7 ]
N-(5-cyanopentyl)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyrazine-3-carboxamide [ No CAS ]

Reference： [1]Patent: US2016/176880,2016,A1

51
[ 19064-18-7 ]
ethyl 8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyrazine-3-carboxylate [ No CAS ]

Reference： [1]Patent: US2017/313700,2017,A1
[2]Patent: US2018/22751,2018,A1
[3]Patent: US2016/176880,2016,A1

52
[ 19064-18-7 ]
8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyrazine-3-carboxylic acid [ No CAS ]

Reference： [1]Patent: US2017/313700,2017,A1
[2]Patent: US2018/22751,2018,A1
[3]Patent: US2016/176880,2016,A1

53
[ 19064-18-7 ]
[ 106308-60-5 ]

Reference： [1]Green Chemistry,2016,vol. 18,p. 4947 - 4953

54
[ 19064-18-7 ]
[ 217448-86-7 ]

Reference： [1]Green Chemistry,2016,vol. 18,p. 4947 - 4953

55
[ 19064-18-7 ]
1-amino-2-[(2,6-difluorobenzyl)oxy]pyridinium 2,4,6-trimethylbenzenesulfonate [ No CAS ]